Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies
Braz. j. med. biol. res
;
45(11): 1095-1101, Nov. 2012. ilus, tab
Article
Dans Anglais
| LILACS
| ID: lil-650576
ABSTRACT
Effective statin therapy is associated with a marked reduction of cardiovascular events. However, the explanation for full benefits obtained for LDL cholesterol targets by combined lipid-lowering therapy is controversial. Our study compared the effects of two equally effective lipid-lowering strategies on markers of cholesterol synthesis and absorption. A prospective, open label, randomized, parallel design study, with blinded endpoints, included 116 subjects. We compared the effects of a 12-week treatment with 40 mg rosuvastatin or the combination of 40 mg simvastatin/10 mg ezetimibe on markers of cholesterol absorption (campesterol and β-sitosterol), synthesis (desmosterol), and their ratios to cholesterol. Both therapies similarly decreased total and LDL cholesterol, triglycerides and apolipoprotein B, and increased apolipoprotein A1 (P < 0.05 vs baseline for all). Simvastatin/ezetimibe increased plasma desmosterol (P = 0.012 vs baseline), and decreased campesterol and β-sitosterol (P < 0.0001 vs baseline for both), with higher desmosterol (P = 0.007) and lower campesterol and β-sitosterol compared to rosuvastatin, (P < 0.0001, for both). In addition, rosuvastatin increased the ratios of these markers to cholesterol (P < 0.002 vs baseline for all), whereas simvastatin/ezetimibe significantly decreased the campesterol/cholesterol ratio (P = 0.008 vs baseline) and tripled the desmosterol/cholesterol ratio (P < 0.0001 vs baseline). The campesterol/cholesterol and β-sitosterol/cholesterol ratios were lower, whereas the desmosterol/cholesterol ratio was higher in patients receiving simvastatin/ezetimibe (P < 0.0001 vs rosuvastatin, for all). Pronounced differences in markers of cholesterol absorption and synthesis were observed between two equally effective lipid-lowering strategies.
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Pyrimidines
/
Sulfonamides
/
Azétidines
/
Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase
/
Simvastatine
/
Fluorobenzènes
/
Hypercholestérolémie
/
Cholestérol LDL
/
Anticholestérolémiants
Type d'étude:
Essai clinique contrôlé
/
Étude observationnelle
/
Facteurs de risque
Limites du sujet:
Adulte
/
Adulte très âgé
/
Femelle
/
Humains
/
Mâle
langue:
Anglais
Texte intégral:
Braz. j. med. biol. res
Thème du journal:
Biologie
/
Médicament
Année:
2012
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Instituto Nacional de Ciência e Tecnologia de Fluidos Complexos/BR
/
Synchrophar/BR
/
Universidade Federal de São Paulo/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS